JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB99298

Recombinant Human 15-PGDH protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human 15-PGDH protein is a Human Full Length protein, in the 1 to 266 aa range, expressed in Escherichia coli, with >95%, suitable for SDS-PAGE, Mass Spec.

View Alternative Names

PGDH1, SDR36C1, HPGD, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], 15-PGDH, Eicosanoid/docosanoid dehydrogenase [NAD(+)], Prostaglandin dehydrogenase 1, Short chain dehydrogenase/reductase family 36C member 1

1 Images
SDS-PAGE - Recombinant Human 15-PGDH protein (AB99298)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human 15-PGDH protein (AB99298)

15% SDS-PAGE showing ab99298 (3μg).

Key facts

Purity

>95% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

Mass Spec, SDS-PAGE

applications

Biologically active

No

Accession

P15428

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 20% Glycerol (glycerin, glycerine), 0.58% Sodium chloride, 0.316% Tris HCl, 0.0154% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMHVNGKVALVTGAAQGIGRAFAEALLLKGAKVALVDWNLEAGVQCKAALDEQFEPQKTLFIQCDVADQQQLRDTFRKVVDHFGRLDILVNNAGVNNEKNWEKTLQINLVSVISGTYLGLDYMSKQNGGEGGIIINMSSLAGLMPVAQQPVYCASKHGIVGFTRSAALAANLMNSGVRLNAICPGFVNTAILESIEKEENMGQYIEYKDHIKDMIKYYGILDPPLIANGLITLIEDDALNGAIMKITTSKGIHFQDYDTTPFQAKTQ","proteinLength":"Full Length","predictedMolecularWeight":"31.1 kDa","actualMolecularWeight":null,"aminoAcidEnd":266,"aminoAcidStart":1,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P15428","tags":[{"tag":"His","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

15-PGDH also known as 15-hydroxyprostaglandin dehydrogenase PGDH or 15-PGDH protein is an enzyme with a molecular mass of approximately 29 kDa. This enzyme catalyzes the oxidation of the 15-hydroxyl group in prostaglandins specifically converting Prostaglandin E2 (PGE2) into its inactive form. Expression occurs in various tissues including the lung placenta and colonic epithelium. Its activity levels can vary depending on the tissue context and physiological conditions marking its importance in local regulation.
Biological function summary

15-PGDH regulates prostaglandin levels which are lipid compounds playing roles in inflammation and homeostasis. This enzyme does not associate with protein complexes but serves a standalone function in metabolic pathways. It maintains a balance between prostaglandin synthesis and degradation ensuring that inflammatory responses do not exceed what is necessary. The enzyme's activity directly reduces available prostaglandins which in turn dampens related signaling pathways.

Pathways

Prostaglandins and this enzyme are part of arachidonic acid metabolism and the Cyclooxygenase (COX) pathway. These pathways play key roles in inflammation and tissue homeostasis. 15-PGDH interacts with other enzymes like COX-2 as it acts downstream to mitigate PGE2 levels generated by COX enzymes. This diminishes the signaling of other elements such as the AMPA receptors involved in neuronal plasticity and pain perception showcasing the enzyme's regulatory scope within biological systems.

15-PGDH plays a role in colon cancer and pulmonary inflammation. Low expression or activity of this enzyme is associated with increased PGE2 levels contributing to cancer progression and chronic inflammation. This dysregulation may involve proteins like COX-2 where the imbalance between synthesis and degradation leads to elevated prostaglandin signaling. Understanding 15-PGDH functions offers insights into therapeutic potentials making inhibitors and potentiators of interest for treatment of these conditions.

Specifications

Form

Liquid

Additional notes

ab99298 is purified using conventional chromatography techniques.

General info

Function

Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed : 10837478, PubMed : 16757471, PubMed : 16828555, PubMed : 21916491, PubMed : 25586183, PubMed : 8086429). Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression (PubMed : 15574495, PubMed : 25586183). Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed : 16757471, PubMed : 22844113).

Sequence similarities

Belongs to the short-chain dehydrogenases/reductases (SDR) family.

Product protocols

Target data

Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed : 10837478, PubMed : 16757471, PubMed : 16828555, PubMed : 21916491, PubMed : 25586183, PubMed : 8086429). Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression (PubMed : 15574495, PubMed : 25586183). Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed : 16757471, PubMed : 22844113).
See full target information HPGD

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com